Skip to main content
Premium Trial:

Request an Annual Quote

PanVera President to Pull Double Duty as Head of Aurora Biosciences

NEW YORK, March 14 - Vertex Pharmaceuticals on Thursday has appointed Michael Wokasch president of its Aurora Biosciences unit.

 

Wokasch is already president of another Vertex subsidiary, PanVera, and will retain that role. At Aurora, he replaces Harry Stylli, who left the firm.

 

Wokasch will help the company broaden its customer base and expand customer relationships, said Vertex chairman and CEO Joshua Boger in a statement.

 

Vertex acquired Aurora last year in order to expand its drug discovery in G-protein coupled receptor and ion channel genes.

 

PanVera is a recombinant protein manufacturer that Aurora snapped up in 2000 for about $36 million. Wokasch became PanVera's president in July 2001.

 

Prior to that, he was CEO and president of startup Gala Design.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.